No profile data available.
Oncolys BioPharma Inc. (4588.T) is a healthcare company in the brain and nerve treatment drugs industry, based in Minato, Japan, with about 45 full-time employees.
It reported revenue of 28.55 million JPY for fiscal year 2025, down 9.0% from fiscal year 2024, and net income of -2.06 billion JPY. Its market capitalization was 175.76 billion JPY as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia.
Oncolys BioPharma reported 28.55 million JPY in revenue for fiscal year 2025, down 9.0% from 31.38 million JPY in fiscal year 2024.
175.76 billion JPY as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include SanBio Company Limited (4592.T), K Pharma,Inc. (4896.T), Kringle Pharma, Inc. (4884.T), MedRx Co., Ltd (4586.T).